Welcome to LookChem.com Sign In|Join Free
  • or
Phosphonium, (6-bromohexyl)triphenyl-, bromide is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

83152-22-1

Post Buying Request

83152-22-1 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

83152-22-1 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 83152-22-1 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,3,1,5 and 2 respectively; the second part has 2 digits, 2 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 83152-22:
(7*8)+(6*3)+(5*1)+(4*5)+(3*2)+(2*2)+(1*2)=111
111 % 10 = 1
So 83152-22-1 is a valid CAS Registry Number.

83152-22-1SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 14, 2017

Revision Date: Aug 14, 2017

1.Identification

1.1 GHS Product identifier

Product name 6-bromohexyl(triphenyl)phosphanium,bromide

1.2 Other means of identification

Product number -
Other names -

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:83152-22-1 SDS

83152-22-1Relevant academic research and scientific papers

Two-photon fluorescence probes for imaging of mitochondria and lysosomes

Yang, Wanggui,Chan, Pui Shan,Chan, Miu Shan,Li, King Fai,Lo, Pik Kwan,Mak, Nai Ki,Cheah, Kok Wai,Wong, Man Shing

, p. 3428 - 3430 (2013)

Novel biocompatible cyanines show not only a very large two-photon cross-section of up to 5130 GM at 910 nm in aqueous medium for high-contrast and -brightness two-photon fluorescence live cell imaging but also highly selective subcellular localization properties including localization of mitochondria and lysosomes.

Antibiotic modified anticancer compounds for the treatment of non-genetic anti-cancer and anticancer pharmaceutical composition comprising the same

-

Paragraph 0062-0065, (2021/08/05)

The present invention relates to an antibiotic modified anti-cancer compound for gene non-toxic anticancer therapy and an anticancer pharmaceutical composition comprising the same. A method for treating mitochondria target using a compound according to th

The AIE-Active Dual-Cationic Molecular Engineering: Synergistic Effect of Dark Toxicity and Phototoxicity for Anticancer Therapy

Ma, Yucheng,Zhuang, Zeyan,Xing, Longjiang,Li, Jianqing,Yang, Zhiwen,Ji, Shaomin,Hu, Rong,Zhao, Zujin,Huo, Yanping,Tang, Ben Zhong

, (2021/09/13)

The development of anticancer therapy is significant to human health but remains a huge challenge. Photodynamic therapy (PDT), inducing the synergistic mitochondrial dysfunction in cancer cells is a promising approach but suffer from the low efficiency in hypoxic microenvironment and deep-seated tumors. Herein, to improve the outcomes of PDT for cancer treatment, a series of red fluorophores consisting of dual-cationic triphenylphosphonium-alkylated pyridinium and (substituted) triphenylamine are prepared as organelle-targeting antitumor photosensitizers (PSs) with aggregation-induced emission characteristics. These PSs can selectively accumulate at the mitochondria or lysosomes of cancer cells with both dark- and photo-cytotoxicity, making them possess excellent killing effect on cancer cells and efficient inhibition of tumor growth in living mice. This study brings about new insight into the development of powerful cancer treatment.

Composition for antibacterial activity of multi-drug resistant bacteria

-

Paragraph 0069, (2021/09/07)

The present invention relates to an antibacterial composition having antibacterial activity against antibiotic resistant strains. , The composition according to the present invention is a positively charged lipophilic cationic compound and a triphenyroniu

ANTICANCER PRODRUG FOR OVERCOMING DRUG RESISTANCE

-

Paragraph 0095-0096, (2020/05/14)

Disclosed is an anticancer prodrug that disturbs energy metabolism in cancer cells to overcome drug resistance. The anticancer prodrug has a structure including a pyruvate dehydrogenase kinase (PDK) inhibitor moiety, a mitochondrial targeting group, and a

Radiation protection compound as well as synthesis method and application thereof

-

Paragraph 0057; 0062-0063, (2020/05/01)

The invention discloses a radiation protection compound with a structural general formula (I) or (II). The synthesis method comprises the steps: enabling triphenylphosphine to react with 6-bromohexanoic acid or 1,6-dibromohexane to obtain a triphenylphosp

Triphenylamine-triphenylphosphine compound as well as preparation method and application thereof

-

Paragraph 0045; 0049-0051, (2020/11/23)

The invention discloses a triphenylamine triphenylphosphine compound as well as a preparation method and application thereof. The triphenylamine triphenylphosphine compound has a molecular structure as shown in a formula (I), wherein R is one of a hydrogen atom, halogen, methoxyl and diphenyl oxide. The triphenylamine triphenylphosphine compound is of an electron-donating and electron-withdrawingstructure (DA) or has a plurality of heavy atoms, intersystem crossing can be promoted, and oxygen can be converted into superoxide free radicals under low exciting light; in addition, the triphenylamine triphenylphosphine compound disclosed by the invention not only has the double functions of photodynamic therapy and mitochondria-mediated cancer cell apoptosis, but also has the AIE performance,has better fluorescence characteristic, and can be used for preparing a photodynamic therapy drug for cancer cell apoptosis, and the photodynamic therapy and mitochondria-mediated cancer cell apoptosis can be effectively inhibited.

Mitochondrial Relocation of a Common Synthetic Antibiotic: A Non-genotoxic Approach to Cancer Therapy

Sunwoo, Kyoung,Won, Miae,Ko, Kyung-Phil,Choi, Miri,Arambula, Jonathan F.,Chi, Sung-Gil,Sessler, Jonathan L.,Verwilst, Peter,Kim, Jong Seung

supporting information, p. 1408 - 1419 (2020/04/15)

Tumor recurrence as a result of therapy-induced nuclear DNA lesions is a major issue in cancer treatment. Currently, only a few examples of potentially non-genotoxic drugs have been reported. Mitochondrial re-localization of ciprofloxacin, one of the most

Overcoming Drug Resistance by Targeting Cancer Bioenergetics with an Activatable Prodrug

Sharma, Amit,Lee, Min-Goo,Shi, Hu,Won, Miae,Arambula, Jonathan F.,Sessler, Jonathan L.,Lee, Jin Yong,Chi, Sung-Gil,Kim, Jong Seung

supporting information, p. 2370 - 2383 (2018/11/23)

Nearly without exception, all known cancer chemotherapeutics elicit a resistance response over time. The resulting resistance is correlated with poor clinical outcomes. Here, we report an approach to overcoming resistance through reprogramming oncogene-di

Preparation of mitochondrion-targeting radioprotectant and application of mitochondrion-targeted radioprotectant in radiation damage protection

-

Paragraph 0019; 0020; 0023, (2019/01/08)

The invention relates to preparation of a mitochondrion-targeting radioprotectant and an application of the mitochondrion-targeting radioprotectant in radiation damage protection and belongs to the technical field of medicine. The medicine combines free r

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 83152-22-1